AMLX Amylyx Pharmaceuticals, Inc. Stock Quote

AMLX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.77	Insider Own	9.90%	Shs Outstand	58.28M	Perf Week	-25.51%
Market Cap	1.36B	Forward P/E	-	EPS next Y	-1.87	Insider Trans	-0.80%	Shs Float	40.88M	Perf Month	-27.88%
Income	-153.40M	PEG	-	EPS next Q	-0.93	Inst Own	55.70%	Short Float	8.32%	Perf Quarter	49.04%
Sales	0.30M	P/S	4547.20	EPS this Y	-108.00%	Inst Trans	8.18%	Short Ratio	3.89	Perf Half Y	-32.33%
Book/sh	3.31	P/B	5.41	EPS next Y	54.30%	ROA	-	Target Price	30.75	Perf Year	-
Cash/sh	2.71	P/C	6.60	EPS next 5Y	-	ROE	-	52W Range	6.51 - 33.41	Perf YTD	-0.94%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	54.70%	52W High	-12.87%	Beta	-
Dividend %	-	Quick Ratio	8.00	Sales past 5Y	-	Gross Margin	-	52W Low	347.16%	ATR	2.19
Employees	205	Current Ratio	8.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	61.71	Volatility	17.73% 9.50%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-139.00%	Profit Margin	-	Rel Volume	41.07	Prev Close	17.90
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 11 AMC	Payout	-	Avg Volume	873.85K	Price	29.11
Recom	1.80	SMA20	20.61%	SMA50	25.80%	SMA200	54.72%	Volume	7,127,687	Change	62.63%

May-25-22

Initiated

Citigroup

Buy

$21

Apr-01-22

Downgrade

Goldman

Buy → Neutral

$36 → $10

Sep-08-22 10:09AM	Controversial ALS Drug From Amylyx Gets Rare Second FDA Meeting Bloomberg +62.63%
09:59AM	Amylyx ALS drug backed by FDA, malaria vaccine data looks encouraging Yahoo Finance Video
09:39AM	Amylyx ALS Drug Wins Backing of FDA Advisory Panel. The Stock Spikes. Barrons.com
Sep-07-22 07:45PM	Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS Business Wire
06:59PM	Amylyxs ALS Drug Backed by FDA Advisers The Wall Street Journal
06:54PM	FDA advisors give thumbs-up to ALS drug with major caveat American City Business Journals
06:47PM	UPDATE 2-Amylyx's ALS drug gets U.S. FDA panel's backing in rare turnaround Reuters
10:00AM	Amylyx Pharmaceuticals Stock Trading Halted Today Business Wire
02:30AM	The FDA Is Giving Amylyx Another Chance on Its ALS Drug. What to Expect. Barrons.com
Sep-06-22 03:12PM	FDA Again Highlights Lacking Data From Amylyx's Amyotrophic Lateral Sclerosis Candidate Benzinga -5.14%
Sep-02-22 04:12PM	The FDA's Mixed Messages Sent Amylyx Pharmaceuticals Stock Off A Cliff Investor's Business Daily -23.19%
12:15PM	Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035 Business Wire
Aug-29-22 08:00AM	These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year Investor's Business Daily
Aug-11-22 04:01PM	Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results Business Wire
Aug-10-22 08:38AM	Is a Surprise Coming for Amylyx Pharmaceuticals (AMLX) This Earnings Season? Zacks
Aug-03-22 09:00AM	Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022 Business Wire
Jul-29-22 09:00AM	Amylyx Pharmaceuticals Announces ALBRIOZA is Now Available in Canada for the Treatment of ALS Business Wire
Jul-18-22 06:00PM	7 Biotech Stocks to Buy for Q3 InvestorPlace
09:00AM	Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases Business Wire
Jul-06-22 09:00AM	Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases Business Wire +5.59%
Jul-05-22 04:12PM	Why IPO Stock Amylyx Pharmaceuticals Is Beginning To Heat Up Again Investor's Business Daily
12:46PM	Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today Motley Fool
09:23AM	UPDATE 2-U.S. FDA to reconvene experts' meeting for Amylyx ALS drug Reuters
09:00AM	Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022 Business Wire
Jun-28-22 02:11PM	Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating Investor's Business Daily
Jun-23-22 08:19AM	Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans Simply Wall St. +12.82%
Jun-16-22 10:11AM	The Petri Dish: Amylyx, Alnylam net drug approvals American City Business Journals +5.89%
Jun-14-22 02:58PM	Here's How Citi Views Amylyx Pharma Benzinga +24.54%
08:00AM	CORRECTED-Amylyx's ALS drug would not be cost effective if priced around $170,000- ICER Reuters
Jun-13-22 07:00AM	Canada Approves Amylyxs ALS Drug as U.S. Seeks More Time to Review The Wall Street Journal
07:00AM	Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA for the Treatment of ALS Business Wire
Jun-03-22 04:15PM	Former Red-Hot IPO Amylyx Soars On New Hopes For Its ALS Drug Investor's Business Daily +26.41%
08:20AM	Amylyx says FDA decision date for ALS therapy is now in September; shares jump MarketWatch
07:00AM	Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS Business Wire
May-31-22 06:41AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX): Is Breakeven Near? Simply Wall St.
May-26-22 09:00AM	Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting Business Wire -8.52%
May-16-22 12:21PM	Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization Business Wire
May-12-22 04:01PM	Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results Business Wire +9.20%
May-08-22 10:30AM	What Kind Of Shareholders Hold The Majority In Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Shares? Simply Wall St.
May-05-22 09:56AM	Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS Business Wire -8.30%
Apr-08-22 01:24PM	Insiders in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) are down 25% on their US$830k purchase despite recent gains Simply Wall St.
Apr-02-22 10:00AM	Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting Business Wire
Mar-31-22 04:11PM	Former IPO Scorcher Amylyx Dives After FDA Panel Strikes Down ALS Drug Investor's Business Daily -13.93%
Mar-30-22 07:33PM	Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results Business Wire
07:00PM	Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS Business Wire
05:31PM	UPDATE 3-U.S. FDA panel votes against Amylyx's ALS drug over trial data concerns Reuters
07:00AM	Amylyx Pharmaceuticals Stock Trading Halted Today Business Wire
Mar-29-22 05:45AM	Could Amylyx Pharmaceuticals Have a Blockbuster ALS Treatment? Motley Fool -6.75%
Mar-28-22 04:06PM	Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment Investor's Business Daily -35.96%
12:04PM	Here's Why Amylyx Pharmaceuticals Stock Is Getting Hammered on Monday Motley Fool
10:45AM	Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035 Business Wire
Mar-25-22 04:10PM	Amylyx Stock Jumps As FDA Mulls ALS Drug What To Know Ahead Of FDA Action Investor's Business Daily +15.15%
Mar-18-22 09:00AM	Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035 Business Wire
Mar-17-22 10:50AM	The FDA Has a New Chief. Here Are 5 Key Decisions on Drugs to Watch. Barrons.com
Feb-25-22 08:00AM	Amylyx Pharmaceuticals Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS Business Wire
Feb-23-22 08:00AM	Amylyx Pharmaceuticals Expands Executive Team with Appointment of Gina M. Mazzariello as Chief Legal Officer and General Counsel Business Wire
Feb-16-22 04:05PM	Amylyx Pharmaceuticals Announces FDA Advisory Committee Meeting to Review New Drug Application for AMX0035 for the Treatment of ALS Scheduled for March 30, 2022 Business Wire +6.44%
Feb-11-22 01:00PM	Goldman Sachs: Buy These 2 Stocks Before They Jump 70% (or More) TipRanks
Feb-10-22 08:00AM	Amylyx Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference Business Wire
Feb-03-22 08:00AM	The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals Partner on Real-World Evidence Generation for a Novel Investigational Therapy in ALS with the Goal of Advancing Health Outcomes for Canadians Living with ALS Business Wire

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ALS Invest 1 B.V.	10% Owner	Jul 06	Sale	20.70	60,609	1,254,642	5,895,280	Jul 08 06:44 PM
Cohen Joshua B	Co-Chief Executive Officer	May 05	Option Exercise	0.37	334,520	123,772	2,898,585	May 06 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	May 05	Option Exercise	0.37	334,520	123,772	2,898,585	May 06 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience